Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05035615
Other study ID # CAS-OFLYRICALL-IVDR
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 2, 2021
Est. completion date March 31, 2024

Study information

Verified date October 2023
Source Becton, Dickinson and Company
Contact Maryam Saleminik
Phone 408-518-5037
Email MSaleminik@bd.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is a multi-site, prospective performance study to determine equivalency between the investigational OneFlow Acute Leukemia Panel on the FACSLyric system versus the final clinical diagnosis.


Description:

Hematology laboratories rely on flow cytometry technology (in addition to classic hematological methods) to aid in screening, diagnosing, and monitoring patients with hematological disorders. High speed and broad applicability of flow cytometry allows for the diagnosis. Currently, there are no consensus panels being used; consequently, the leukemia & lymphoma (L&L) testing remains a single-vial antibody being used, with various in-house laboratory developed tests (LDTs) being used to test patient specimens. Furthermore, the analysis of flow cytometer generated data is not standardized and requires a high level of expertise and training for interpretation of complex data. Therefore, optimized and standardized immunostaining protocols for the diagnosis, classification, and prognostic sub-classification of hematological malignancies are needed. Enrollment will occur at up to 8 investigational sites . Data will be acquired from Eligible remnant/leftover specimens on the BD FACSLyric flow cytometer and evaluated by site personnel and expert analysts . The final diagnosis and the affected cell population will be determined by site standard of care . Analysis of data will evaluate identification of 1) normal vs abnormal cell populations and 2) BCP-ALL, AML, and less certain diseases by the expert & site analysts as compared to the final diagnosis.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date March 31, 2024
Est. primary completion date March 31, 2024
Accepts healthy volunteers No
Gender All
Age group 3 Years and older
Eligibility Inclusion Criteria: 1. Specimen collected/handled prior to enrollment in accordance with site policies and procedures. 2. Specimen with adequate volume (1 mL) to complete protocol tests. 3. Specimen is leftover PB and BM from routine flow cytometry laboratory testing for having or suspected of having acute leukemia disorders (i.e. AML, BCP-ALL, ALAL, etc.), myelodysplastic syndrome (MDS), other hematological, or non-hematological disorders. 4. Specimen from newly diagnosed or relapsed subject. 5. Only one specimen type (PB or BM) shall be enrolled per given subject. 6. Specimen is stored at room temperature, upon receipt by the site. 7. Specimens are collected in EDTA (K2 or K3) or heparin (sodium or lithium). 8. Age of specimen (BCP ALL T1: time of collection to start of first pre-wash; ALOT, AML T1-T4: time of collection to start of staining): = 24 hours. 9. Specimens are from subjects irrespective of race, gender, and ethnicity Exclusion Criteria: 1. Specimen is from healthy subject. 2. Specimen from subject <3 years of age. 3. Specimen is from subject undergoing any treatment for any form of leukemia. 4. Specimen is from subject with minimal residual disease (MRD) as determined by the site. 5. Specimen is from subject suspected of plasma cell disorders. 6. Visibly clotted specimen. 7. Visibly hemolyzed specimen. 8. Frozen specimen. 9. Refrigerated specimen. 10. Fixed specimen.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
IUO Acute Leukemia Panel
This Investigational Panel , comprised of 6 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of immature hematopoietic cell populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, B-cell acute lymphoblastic leukemia or acute myeloid leukemia.

Locations

Country Name City State
Brazil Fleury Group San Paolo
Czechia Motol University Hospital, Childhood Leukemia Investigation Prague
Spain University of Salamanca Salamanca
United Kingdom Cambridge University Cambridge
United States University Of North Carolina Chapel Hill North Carolina
United States Childrens Hospital Los Angeles Los Angeles California
United States New York-Presbyterian Hospital Weill Cornell Medicine New York New York
United States CorePath Laboratories San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
Becton, Dickinson and Company

Countries where clinical trial is conducted

United States,  Brazil,  Czechia,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison between expert analysts' determination of normal and abnormal specimen and final diagnosis (Sensitivity Analysis) Determine equivalence between the investigational OneFlow Acute Leukemia Panel on the BD FACSLyric system results analyzed by two independent experts versus the final clinical diagnosis for Normal (lymphoid and myeloid) or Abnormal (neoplastic lymphoid or myeloid) phenotypes.
Sensitivity will be calculated
Within 24 Hours of specimen collection
Primary Comparison between expert analysts' determination of normal and abnormal specimen and final diagnosis (Specificity Analysis) Determine equivalence between the investigational OneFlow Acute Leukemia Panel on the BD FACSLyric system results analyzed by two independent experts versus the final clinical diagnosis for Normal (lymphoid and myeloid) or Abnormal (neoplastic lymphoid or myeloid) phenotypes.
Specificity will be calculated
Within 24 Hours of specimen collection
See also
  Status Clinical Trial Phase
Recruiting NCT05088356 - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Phase 1
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2
Recruiting NCT02356159 - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Phase 1/Phase 2
Withdrawn NCT05170828 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1
Recruiting NCT02930109 - A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia Phase 1/Phase 2
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Active, not recruiting NCT01956630 - Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT Phase 1/Phase 2
Completed NCT00988013 - Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies N/A
Enrolling by invitation NCT01728402 - Pathogenesis of Hematologic Malignancies
Active, not recruiting NCT03595800 - Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen Phase 3
Completed NCT02440178 - Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia Phase 2
Recruiting NCT05071482 - Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL Phase 4
Completed NCT03042676 - Electronic Database for the Follow up of the ATG_FamilyStudy
Withdrawn NCT03138395 - iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML N/A
Completed NCT04597086 - Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients N/A
Terminated NCT03588936 - Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant Phase 1
Recruiting NCT05521204 - Olverembatinib for FGFR1-rearranged Neoplasms Phase 2
Not yet recruiting NCT04084327 - Immunophenotyping of Acute b Cell Lymphoblstic Leukemia
Terminated NCT00852709 - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias Phase 1